The Optima HIV model was launched in 2012 but precursors to the model were in development from 2004. Since the Optima launch in 2012, the model has been applied worldwide.
Findings from Optima HIV applications and studies have been used to inform: the United Nations General Assembly, Global Fund to Fight AIDS, Tuberculosis and Malaria, Association of Southeast Asian Nations, national HIV/AIDS Strategic Plans, national Global Fund Concept Note applications, and country reports.
The Optima HIV software was conceptualised and developed by the Optima Consortium for Decision Science with technical input from the World Bank, and is owned by Optima Consortium for Decision Science, Ltd. Optima HIV can be reached through and is free and open source, with the code available for download on GitHub.
Optima HIV helps to:
2004–ongoing.
HIV 'care cascade' of testing, treatment and recovery.
HIV can be transmitted through sex, injecting activities and perinatal exposure.
Optima HIV is a software tool that assists users in determining the optimal allocation optimal allocation of HIV resources and coverage levels across programs in specific HIV epidemic settings.
Optima HIV User Guide Overview [DOCX 285.1 kB]Workshop agenda and training materials.
HIV allocative efficiency analysis training English [PDF 12.9 MB]Findings from Optima HIV modelling analyses across 12 countries in Eastern Europe and Central Asia.
Allocation of HIV resources towards maximizing the impact of funding in selected Eastern European and Central Asian countries [PDF 3.5 MB]Optimizing spending would involve prioritizing antiretroviral therapy scale up where possible before prevention programs for female sex workers, men who have sex with men and people who inject drugs.
Allocation of HIV resources in Albania [PDF 1.6 MB]Optimizing spending would involve scaling up antiretroviral therapy and prevention programs for migrants ahead of prevention programs focusing on female sex workers and men who have sex with men.
Allocation of HIV resources in Armenia [PDF 1.6 MB]Optimizing spending would involve deprioritizing HIV testing for the general population to enable continued scale up of treatment, as well as HIV programs for men who have sex with men and people who inject drugs.
Allocation of HIV resources in Azerbaijan [PDF 1.6 MB]Optimizing spending would involve deprioritizing HIV testing among the general population to enable continued scale up of ART for all populations and HIV prevention and testing programs for people who inject drugs.
Allocation of HIV resources in Belarus [PDF 1.8 MB]HIV spending allocations in Georgia are estimated to be close to optimized already, with prioritisation of effective key population programs.
Allocation of HIV resources in Georgia [PDF 1.6 MB]Optimizing spending would involve deprioritising HIV testing among the general population to enable continued scale up of antiretroviral therapy, pre-exposure prophylaxis for men who have sex with men, and needle-syringe programs for people who inject drugs.
Allocation of HIV resources in Kazakhstan [PDF 1.8 MB]The current HIV spending allocation is estimated to be close to optimised. Further optimisation would explore opportunities to scale up antiretroviral therapy coverage by improving linkage and retention to treatment, and strategic information about people who leave the county for treatment in other settings.
Allocation of HIV resources in Kosovo [PDF 1.6 MB]Optimizing spending would involve deprioritizing HIV testing for the general<br/>population to enable continued scale up of antiretroviral therapy and maintain spending for programs for people who inject drugs.
Allocation of HIV resources in Kyrgyzstan [PDF 1.7 MB]Optimizing spending would involve deprioritizing condom promotion and distribution, needle-syringe programs (NSP) and prevention programs for female sex workers, to continue scaling up antiretroviral therapy for all populations and HIV programs for men who have sex with men.
Allocation of HIV resources in Moldova [PDF 3.0 MB]Potential savings from reduced antiretroviral therapy unit costs could be reinvested among HIV programs funded by the Republic Health Insurance Fund; optimally this would include further scale-up of antiretroviral therapy followed by investment in pre-exposure prophylaxis (PrEP).
Allocation of HIV resources in Serbia [PDF 1.7 MB]Optimizing spending would involve continued scale up of antiretroviral therapy and a shift in emphasis toward HIV programs for female sex workers and migrants while maintaining substantial investment in programs for people who inject drugs.
Allocation of HIV resources in Tajikistan [PDF 1.6 MB]We estimated the optimized resource allocations within counties, whereby the total HIV budget for each county was kept the same, and across counties, where resources could be shifted between counties.
Allocation of HIV resources in Uzbekistan [PDF 1.7 MB]We estimated the optimized resource allocations within counties, whereby the total HIV budget for each county was kept the same, and across counties, where resources could be shifted between counties.
Improving allocative efficiency of the HIV response in Kenya [PDF 5.0 MB]The main purpose of this analysis is to develop an investment scenario that maximises the impact of resource allocations in HIV prevention, tailored to the needs of key populations, differentiated to subpopulations by risk and age, and aligned with the Global AIDS Strategy.
Ending the AIDS epidemic in Cambodia [PDF 8.2 MB]Allocative efficiency modeling analyses were conducted in 11 countries in EECA through partnership with the country Governments, the Global Fund to Fight AIDS, Tuberculosis and Malaria, UNAIDS, and Burnet Institute. Participating countries included Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Romania, Tajikistan, Ukraine, and Uzbekistan.
Resource optimization to maximize the HIV response in Eastern Europe and Central Asia [PDF 804.4 kB]Результаты анализа с применением модели Optima HIV для 11 стран Восточной Европы и Центральной Азии.
Оптимизация ресурсов для максимизации противодействия эпидемии ВИЧ в Восточной Европе и Центральной Азии [PDF 852.6 kB]This report outlines findings from an HIV modeling analysis conducted for Malawi by the country team, the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Clinton Health Access Initiative (CHAI), and the Optima Consortium for Decision Science.
Improving efficiency of the HIV response in Malawi [PDF 2.2 MB]An allocative efficiency modeling analysis was conducted through partnership with the Armenian Government, the Global Fund, UNAIDS and Burnet Institute. The Optima HIV model was applied to estimate the optimized resource allocation across a mix of HIV programs.
Resource optimization to maximize the HIV response in Armenia [PDF 931.4 kB]An allocative efficiency modeling analysis was conducted through partnership with the Azerbaijani Government, the Global Fund, UNAIDS and Burnet Institute. The Optima HIV model was applied to estimate the optimized resource allocation across a mix of HIV programs.
Resource optimization to maximize the HIV response in Azerbaijan [PDF 1.2 MB]An allocative efficiency modeling analysis was conducted through partnership with the Belarusian Government, the Global Fund, UNAIDS and Burnet Institute. The Optima HIV model was applied to estimate the optimized resource allocation across a mix of HIV programs.
Resource optimization to maximize the HIV response in Belarus [PDF 920.3 kB]An allocative efficiency modeling analysis was conducted through partnership with the Georgian Government, the Global Fund, UNAIDS and Burnet Institute. The Optima HIV model was applied to estimate the optimized resource allocation across a mix of HIV programs.
Resource optimization to maximize the HIV response in Georgia [PDF 860.5 kB]An allocative efficiency modeling analysis was conducted through partnership with the Kazak Government, the Global Fund, UNAIDS and Burnet Institute. The Optima HIV model was applied to estimate the optimized resource allocation across a mix of HIV programs.
Resource optimization to maximize the HIV response in Kazakhstan [PDF 937.4 kB]An allocative efficiency modeling analysis was conducted through partnership with the Kyrgyz Government, the Global Fund, UNAIDS and Burnet Institute. The Optima HIV model was applied to estimate the optimized resource allocation across a mix of HIV programs.
Resource optimization to maximize the HIV response in Kyrgyzstan [PDF 1.5 MB]An allocative efficiency modeling analysis was conducted through partnership with the Moldovan Government, the Global Fund, UNAIDS, and Burnet Institute. The Optima HIV model was applied to estimate the optimized resource allocation across a mix of HIV programs.
Resource optimization to maximize the HIV response in Moldova [PDF 1.4 MB]An allocative efficiency modeling analysis was conducted through partnership with the Government of Romania, the Global Fund, UNAIDS and Burnet Institute. The Optima HIV model was applied to estimate the optimized resource allocation across a mix of HIV programs.
Resource optimization to maximize the HIV response in Romania [PDF 1.0 MB]An allocative efficiency modeling analysis was conducted through partnership with the Tajikistani Government, the Global Fund, UNAIDS, and Burnet Institute. The Optima HIV model was applied to estimate the optimized resource allocation across a mix of HIV programs.
Resource optimization to maximize the HIV response in Tajikistan [PDF 890.3 kB]An allocative efficiency modeling analysis was conducted through partnership with the Ukrainian Government, the Global Fund, UNAIDS and Burnet Institute. The Optima HIV model was applied to estimate the optimized resource allocation across a mix of HIV programs.
Resource optimization to maximize the HIV response in Ukraine [PDF 1.3 MB]Efficiency is needed in the response to further the progress towards national HIV targets. To address this need, a 2-phased HIV epidemic and allocative and implementation efficiency analysis of the HIV response, with a particular focus on the HIV testing and treatment cascade was conducted using Optima HIV. Optima HIV is a mathematical model for determining an optimized resource allocation across a combination of HIV programs for maximizing defined outcomes such as reductions in incidence and deaths.
Improving the allocative efficiency of the HIV response across the care cascade in Zimbabwe [PDF 5.2 MB]An allocative efficiency analysis of Kosovo’s HIV response was conducted using Optima HIV, an epidemiological model of HIV transmission that is coupled with a programmatic component and a resource optimization algorithm.
Improving the allocative efficiency of Kosovo’s HIV response [PDF 1.4 MB]In the hopes of assisting the Government of Mexico in further strengthening its HIV investment, the authors try to answer the question How can HIV funding be optimally allocated to the combination of HIV response interventions that will yield the highest impact in the shortest period.
Optimizing investments in the national HIV response of MexicoEl objetivo del estudio es mejorar la eficiencia distributiva del gasto nacional en el control del VIH, en apoyo a las políticas nacionales sobre el tema, utilizando una herramienta matemática elaborada conjuntamente por el Banco Mundial y el “Optima Consortium for Decision Science”, denominada ÓPTIMA-VIH.
Optimizando la inversión del plan de respuesta de Colombia al VIH [PDF 2.1 MB]The report summarizes the findings of an allocative efficiency analysis of Myanmar's national HIV epidemic and response.
Allocating HIV funding efficiently in MyanmarThe objective of the analysis was to determine (i) the optimal programmatic funding allocations to minimise new HIV infections and deaths and (ii) the optimal programmatic funding allocations to achieve specific impact and coverage targets at the lowest costs in the medium-term.
Allocative efficiency analysis HIV 2015–2030 for Karnataka and PunjabÓptimao VIH es un modelo matemático sobre la transmisión y progresión del VIH, integrado en un marco de análisis económico y programas orientados a VIH.
Optimización de las inversiones para la respuesta al VIH en PerúThis report summarizes the findings of an allocative efficiency analysis of Togo’s HIV response.
Optimizing investments for HIV response in TogoEl objetivo del estudio es realizar el análisis de eficiencia distributiva de VIH mediante una herramienta técnica denominada Óptima VIH.
Optimización de la inversión en VIH/SIDA en ArgentinaThis brief provides the key results of a modeling analysis estimating what it would take in terms of programmatic targets and costs for Johannesburg to meet the fast-track targets and demonstrate the impact that this would have.
Ending AIDS in JohannesburgThe report summarizes the findings of an allocative efficiency analysis to support Senegal's national HIV response.
Optimizing investments for a sustainable and efficient HIV response in SenegalThis report summarizes the findings of an allocative efficiency analysis to support Côte d'Ivoire’s national HIV response.
HIV investment in Cote d’IvoireBulgaria's HIV response requires a shared, long-term vision for sustainable HIV financing that harnesses wider health sector reforms and emerging financing models.
Optimizing investments in Bulgaria’s HIV responseThis report summarizes the findings of an allocative efficiency analysis on Belarus's national HIV epidemic and response conducted in 2014-15.
Optimizing investments in Belarus for the national HIV responseThis report summarizes the findings of an allocative efficiency analysis on the Kyrgyz Republic's national HIV epidemic and response conducted in 2014-15.
Optimizing investments in the Kyrgyz Republic’s HIV responseAn HIV allocative efficiency analysis has been carried out, which revealed that there are several key opportunities to change the course of Ukraine’s HIV epidemic.
Value for money in Ukraine’s HIV responseTesting key populations and their sexual partners is the most cost-effective strategy to identify those who require antiretroviral therapy.
Optimizing investments in Georgia’s HIV responseThis report summarizes the findings of an allocative efficiency analysis on Armenia's national HIV epidemic and response conducted in 2014–15.
Optimizing HIV investments in ArmeniaAs part of a regional initiative, Kazakhstan conducted an HIV allocative efficiency analysis in 2014 to 2015 to inform more strategic investment in HIV programs.
Optimizing investments in Kazakhstan’s HIV responseIn March 2014, the United Nations Office on Drugs and Crime organized within the frame of the high-level review of the 57th session of CND, the first scientific consultation in Vienna, entitled 'Science addressing drugs and HIV: state of the art', where it brought together leading scientists to discuss the latest developments in prevention and treatment of HIV and AIDS as it relates to drug use.
Science addressing drugs and HIV: UN second scientific statement [PDF 215.6 kB]Increasing efficiency of HIV programs for people who inject drugs is a key step towards avoiding implicit rationing and transparent allocation of resources where and how they would have the largest impact on the health of people who inject drugs, and thereby ensuring that funding becomes a global best buy in public health.
Efficiency In HIV Harm Reduction [PDF 384.4 kB]A report for World Health Organization Southeast Asia Regional Office. Mathematical modelling was conducted to inform development of the new SEAR Health Sector Strategy on HIV.
Optimizing investments in the national HIV responses of Indonesia and Thailand [PDF 1.0 MB]This brief presents a real-life example of how a group of government decision-makers, program managers, researchers and development partners worked together to improve the allocation of HIV resources in Sudan and thereby better address the HIV objectives that the country strives to achieve.
HIV investment in SudanThis report summarizes the findings of an allocative efficiency analysis on Moldova's national HIV epidemic and response conducted in 2014-15.
Optimizing investments in Moldova’s HIV responseThis report summarizes the findings of an Allocative efficiency analysis on the Former Yugoslav Republic (FYR) of Macedonia's national HIV epidemic and response conducted in 2014-15.
Optimizing investments in Former Yugoslav Republic of Macedonia’s HIV responseWith a moderate increase of the investment volume until 2020 combined with an optimised investment allocation the national HIV response in Uzbekistan can be brought on a trajectory which fulfils the basic rights to access to all essential HIV services for those in need.
Uzbekistan HIV 2020 report [PDF 3.3 MB]This report summarizes findings from an allocative efficiency and financial commitment analysis conducted for the Government of Zambia by the World Bank and the University of New South Wales.
Zambia's HIV responseThis report examines the resource challenges that confront the AIDS response in Asia and the Pacific. It proposes a set of interventions that will help overcome them and steer the region towards ending its AIDS epidemic.
Investing for results: how Asia-Pacific countries can invest for ending AIDS 2015 [PDF 1.0 MB]This report summarizes the findings of an allocative efficiency analysis on Sudan s national HIV epidemic and response conducted in 2014.
Sudan’s HIV responsePresented to the United Nations General Assembly. If the world is to end the AIDS epidemic by 2030, rapid progress must be made by 2020. Quickening the pace for essential HIV prevention and treatment approaches will limit the epidemic to more manageable levels and enable countries to move towards the elimination phase.
UN.General Assembly: optimizing allocation of resources for HIV/AIDS responses [PDF 4.3 MB]To assess the HIV investment case in Swaziland we used a mathematical model of HIV transmission and disease progression called Optima (formerly known as Prevtool).
Swaziland HIV report [PDF 1.8 MB]Presentation slides on the AIDS funding landscape in Asia and the Pacific.
HIV resource needs, availabilities and gaps across ASEAN countries [PDF 1.4 MB]The main objective of the study is to provide a comprehensive analysis of HIV and health financing needs, investment opportunities, and health system development in the context of the Government of Niger's HIV National Strategic Plan 2013-17.
Niger’s HIV responseWith the current changes in the international HIV financing landscape and the anticipated reduction in Global Fund financing, it is expected that the last two years of the Ukraine 2014-‐18 National AIDS Strategy will require increasing domestic resources, or more efficient implementation of the same services. This leaves Ukraine with approximately three years to develop and implement a transition strategy in order to meet its growing HIV response financing challenge.
Ukraine HIV Program Efficiency Report [PDF 6.4 MB]Armenia’s response to its HIV epidemic is underfunded, and currently prevalence and incidence are still increasing. Most of Armenia’s HIV funding has historically come from international sources.
HIV investment in Armenia: analysis and recommendations 2014 [PDF 1.8 MB]With a moderate increase of the investment volume until 2020 combined with an optimized investment allocation the national HIV response in Tajikistan can be brought on a trajectory which fulfils the basic rights to access to essential HIV services for those in need and makes ending the epidemic threat of HIV/AIDS in Tajikistan a realistic goal if an environment without stigma and discrimination is provided so that services available will be accepted and used by the affected communities.
Modelling an optimized investment approach for Tajikistan [PDF 3.6 MB]В стремлении продемонстрировать свою наибольшую политическую приверженность борьбе с ВИЧ и СПИД на самом высоком уровне и воспрепятствовать вредному социально-экономическому воздействию, которому подвергаются сообщества, Национальная программа по борьбе с ВИЧ/СПИД в Таджикистане обратилась к донорскому сообществу с просьбой об оказании технического содействия в моделировании для Таджикистана оптимального инвестиционного подхода в контексте устойчивого финансирования национального реагирования на ВИЧ.
Моделирование подхода оптимизированного инвестирования для Таджикистана [PDF 4.1 MB]Evaluation of a decade of DFID and World Bank supported HIV and AIDS programmes in Vietnam from 2003 to 2012, including DFID's management response.
Evaluation of a decade of DFID and World Bank supported HIV and AIDS programmes in Vietnam from 2003 to 2012Acting strategically now can avert 5,800 HIV infections over 5 years; delaying by 3 years would lead to an unnecessary additional 3,000 infections.
Belarus HIV report 2013 [PDF 8.1 MB]This study aimed to estimate the cost-effectiveness and return on investment of HIV programs implemented during 2003-2010 in Indonesia and to contribute to the allocative efficiency of the HIV prevention response in Indonesia.
Assessment of the allocation of HIV funding in IndonesiaThe PNG HIV Model is a detailed mathematical model of HIV transmission in Papua New Guinea. It was developed as a tool to evaluate and understand HIV epidemic trajectories within Papua New Guinea with the purpose of evaluating the impact of potential HIV interventions and to assist with policy development.
PNG HIV Model Reports [PDF 3.9 MB] PNG HIV Modeling Report Technical Appendix [PDF 1.7 MB] PNG HIV Model Software Manual [PDF 1.1 MB]This study assessed the effectiveness of efforts to distribute needle-syringes and condoms and changing risk behavior to reduce sharing of injecting equipment and engaging in unprotected sex so that HIV transmission rates would decline.
Vietnam WB 2011 [PDF 7.2 MB]The HIV in Indonesia model is flexible for users to define and assess different targeted scenario combinations of past and future epidemic patterns and programs. The model is easily adaptable for application to different geographical levels within Indonesia.
HIV in Indonesia model report [PDF 1.2 MB] HIV in Indonesia model software manual [PDF 416.0 kB]This report will attempt to evaluate the current epidemiology and the 'low and slow' development of the HIV epidemic in the Philippines.
Epidemiology and modeling report on HIV/AIDS in the Philippines [PDF 533.6 kB]Prepared for AusAID, this report presents findings from a study that investigates the potential impact of the economic crisis on HIV epidemics through the use of mathematical modelling.
Impact of global economic crisis on HIV epidemics in Southeast Asia [PDF 771.8 kB]This report suggests promoting condom use and targeting other sexually transmitted infections are the most effective interventions for interrupting HIV in men who have sex with men.
Modelling HIV among men who have sex with men in Australia [PDF 8.3 MB]BMJ Global Health
Anna L. Bowring, Debra ten Brink, Rowan Martin‐Hughes, Nick Scott
JAIDS Journal of Acquired Immune Deficiency Syndromes
Rowan Martin‐Hughes
JAIDS Journal of Acquired Immune Deficiency Syndromes
Sherrie L. Kelly, Rowan Martin‐Hughes
JAIDS Journal of Acquired Immune Deficiency Syndromes
Debra ten Brink, Rowan Martin‐Hughes, Rowan Martin‐Hughes, Debra ten Brink
BMC Public Health
Debra ten Brink, Rowan Martin‐Hughes, Nisaa Wulan
The Lancet Global Health
Debra ten Brink, Rowan Martin‐Hughes, Sherrie L. Kelly
PLoS ONE
Aaron J. Osborne, Debra ten Brink, Rowan Martin‐Hughes, Mark Minnery, David P. Wilson, Sherrie L. Kelly, Debra ten Brink, Rowan Martin‐Hughes, Mark Minnery, Aaron J. Osborne
The Lancet HIV
Rowan Martin‐Hughes, Debra ten Brink, Sherrie L. Kelly
PLoS ONE
Sherrie L. Kelly, Rowan Martin‐Hughes
medRxiv (Cold Spring Harbor Laboratory)
Sherrie L. Kelly, Rowan Martin‐Hughes
International Journal of Drug Policy
Robyn M. Stuart, David P. Wilson
The Lancet HIV
Rowan Martin‐Hughes, Debra ten Brink, Sherrie L. Kelly, Debra ten Brink, Rowan Martin‐Hughes, Sherrie L. Kelly, Debra ten Brink, Rowan Martin‐Hughes, Sherrie L. Kelly
PLoS ONE
Robyn M. Stuart
AIDS
Robyn M. Stuart, Sherrie L. Kelly, Rowan Martin‐Hughes, David P. Wilson
PLoS ONE
Mark Minnery, David Wilson, Sherrie L. Kelly
AIDS
Robyn M. Stuart, Cliff C. Kerr, David Jacob Kedziora, Rowan Martin‐Hughes, Sherrie L. Kelly, David P. Wilson
AIDS
Debra ten Brink, Rowan Martin‐Hughes, Sherrie L. Kelly, David P. Wilson
Pathogens and Disease
Janka Petravic, David P. Wilson
BMC Public Health
David Jacob Kedziora, Robyn M. Stuart, David P. Wilson
AIDS
Robyn M. Stuart, Sherrie L. Kelly, Cliff C. Kerr, Rowan Martin‐Hughes, David P. Wilson
Journal of the International AIDS Society
Robyn M. Stuart, Cliff C. Kerr, David P. Wilson
PLoS ONE
Cliff C. Kerr, David P. Wilson
The Lancet HIV
Janka Petravic, Sherrie L. Kelly, Rowan Martin‐Hughes, Robyn M. Stuart, Xiao F Yap, David Jacob Kedziora, Sheharyar Hussain, Iyanoosh Reporter, Cliff C. Kerr, David P. Wilson
Journal of the International AIDS Society
Iyanoosh Reporter, Robyn M. Stuart, Sherrie L. Kelly, David Jacob Kedziora, Janka Petravic, Sheharyar Hussain, Xiao F Yap, Rowan Martin‐Hughes, Cliff C. Kerr, David P. Wilson
Journal of the International AIDS Society
Robyn M. Stuart, David P. Wilson
Journal of the International AIDS Society
David P. Wilson
Clinical Infectious Diseases
Nick Scott, Mark Stoové, Sherrie L. Kelly, David P. Wilson, Margaret Hellard
Journal of the International AIDS Society
Tafireyi Marukutira, Mark Stoové, Sherrie L. Kelly, David P. Wilson, Stanley Lüchters, Suzanne M. Crowe
Journal of the International AIDS Society
David P. Wilson
PLoS ONE
Robyn M. Stuart, Cliff C. Kerr, Iyanoosh Reporter, Rowan Martin‐Hughes, Sheharyar Hussain, Sherrie L. Kelly, David Jacob Kedziora, David P. Wilson
Journal of the International AIDS Society
Cliff C. Kerr, Robyn M. Stuart, David P. Wilson
AIDS
Kelsey L. Grantham, Cliff C. Kerr, David P. Wilson
Journal of the International AIDS Society
David P. Wilson
The Lancet HIV
Sherrie L. Kelly, David P. Wilson
International Journal of Drug Policy
Sherrie L. Kelly, David P. Wilson
PLoS ONE
Sherrie L. Kelly, David P. Wilson
Journal of the International AIDS Society
Robyn M. Stuart, David P. Wilson
PLoS Medicine
PLoS Medicine
The Lancet HIV
The Lancet Global Health
Journal of Antimicrobial Chemotherapy
International Journal of Drug Policy
JAIDS Journal of Acquired Immune Deficiency Syndromes
The Lancet HIV
JAIDS Journal of Acquired Immune Deficiency Syndromes
The Lancet Global Health
Nature
Sexual Health
Journal of the International AIDS Society
AIDS Patient Care and STDs
The Lancet Global Health
The Lancet
Sexual Health
Clinical Infectious Diseases
PLoS Medicine
PLoS Medicine
PLoS ONE
AIDS
PLoS Medicine
Sexual Health
PLoS ONE
AIDS
Vaccine
Vaccine
Journal of the International AIDS Society
AIDS
JAIDS Journal of Acquired Immune Deficiency Syndromes
The Journal of Infectious Diseases
Current HIV Research
Sexual Health
Current Opinion in HIV and AIDS
Proceedings of the National Academy of Sciences
The Lancet
BMC Medicine
Proceedings of the National Academy of Sciences
PLoS Medicine
HIV Modelling Consortium